KR20180113540A - 혈액암 및 고형 종양의 치료를 위한 idh2 저해제 - Google Patents

혈액암 및 고형 종양의 치료를 위한 idh2 저해제 Download PDF

Info

Publication number
KR20180113540A
KR20180113540A KR1020187024384A KR20187024384A KR20180113540A KR 20180113540 A KR20180113540 A KR 20180113540A KR 1020187024384 A KR1020187024384 A KR 1020187024384A KR 20187024384 A KR20187024384 A KR 20187024384A KR 20180113540 A KR20180113540 A KR 20180113540A
Authority
KR
South Korea
Prior art keywords
compound
idh2
flt3
mutant allele
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187024384A
Other languages
English (en)
Korean (ko)
Inventor
마이클 아마탄젤로
샤오란 휴
안잔 타쿠르타
성 은 최
빈 우
Original Assignee
셀진 코포레이션
아지오스 파마슈티컬스 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀진 코포레이션, 아지오스 파마슈티컬스 아이엔씨. filed Critical 셀진 코포레이션
Publication of KR20180113540A publication Critical patent/KR20180113540A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
KR1020187024384A 2016-02-26 2016-12-02 혈액암 및 고형 종양의 치료를 위한 idh2 저해제 Ceased KR20180113540A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662300673P 2016-02-26 2016-02-26
US62/300,673 2016-02-26
PCT/US2016/064615 WO2017146794A1 (en) 2016-02-26 2016-12-02 Idh2 inhibitors for the treatment of haematological maligancies and solid tumours

Publications (1)

Publication Number Publication Date
KR20180113540A true KR20180113540A (ko) 2018-10-16

Family

ID=57610404

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187024384A Ceased KR20180113540A (ko) 2016-02-26 2016-12-02 혈액암 및 고형 종양의 치료를 위한 idh2 저해제
KR1020187027740A Ceased KR20180114202A (ko) 2016-02-26 2016-12-02 혈액 악성종양 및 고형 종양의 치료를 위한 idh1 억제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187027740A Ceased KR20180114202A (ko) 2016-02-26 2016-12-02 혈액 악성종양 및 고형 종양의 치료를 위한 idh1 억제제

Country Status (12)

Country Link
US (3) US10137130B2 (enExample)
EP (2) EP3419593B1 (enExample)
JP (3) JP6930991B2 (enExample)
KR (2) KR20180113540A (enExample)
CN (1) CN109069410B (enExample)
AU (2) AU2016393869B2 (enExample)
CA (2) CA3015753A1 (enExample)
ES (1) ES2912909T3 (enExample)
IL (2) IL261353A (enExample)
MA (1) MA43640A (enExample)
MX (3) MX390396B (enExample)
WO (2) WO2017146794A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2015010297A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
PH12021551647A1 (en) 2014-03-14 2022-06-06 Agios Pharmaceuticals Inc Pharmaceutical compositions of therapeutically active compounds
WO2016044787A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
CA2961807A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HUE062424T2 (hu) 2014-09-19 2023-11-28 Forma Therapeutics Inc Piridin-2(1H)-on kinolinon származékok mint mutáns izocitrát dehidrogenáz inhibitorok
WO2016044781A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
AU2015324158A1 (en) 2014-09-29 2017-04-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3253746A1 (en) 2015-02-04 2017-12-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9624175B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US10407419B2 (en) 2015-04-21 2019-09-10 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
MD3362066T2 (ro) 2015-10-15 2022-08-31 Les Laboratoires Servier Sas Terapie combinată pentru tratamentul tumorilor maligne
JP2018534288A (ja) 2015-10-15 2018-11-22 アジオス ファーマシューティカルズ， インコーポレイテッド 悪性腫瘍の治療のための併用療法
CA3002029A1 (en) 2015-10-15 2017-04-20 Celgene Corporation Combination therapy for treating malignancies
HUE067449T2 (hu) 2015-10-15 2024-10-28 Servier Lab Ivozidenib, citarabin és daunorubicin vagy idarubicin kombinációs terápa akut mielogén leukémia kezelésére
US12282014B2 (en) 2015-11-19 2025-04-22 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers
WO2018026894A1 (en) * 2016-08-03 2018-02-08 Celgene Corporation Methods of treatment of myelodysplastic syndrome
KR102498693B1 (ko) 2016-09-07 2023-02-10 셀진 코포레이션 정제 조성물
WO2018204787A1 (en) * 2017-05-05 2018-11-08 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
US11709164B2 (en) 2017-10-26 2023-07-25 National University Of Singapore Approach for universal monitoring of minimal residual disease in acute myeloid leukemia
WO2019109095A1 (en) * 2017-12-01 2019-06-06 Beth Israel Deaconess Medical Center, Inc. Arsenic trioxide and retinoic acid compounds for treatment of idh2-associated disorders
EP3746124A4 (en) 2018-01-30 2021-10-27 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
CN118903436A (zh) 2018-01-31 2024-11-08 德西费拉制药有限责任公司 治疗肥大细胞增多症的组合疗法
KR102708177B1 (ko) 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
SMT202300073T1 (it) 2018-05-16 2023-05-12 Forma Therapeutics Inc Inibizione di idh-1 mutante
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CA3103498A1 (en) * 2018-07-06 2020-01-09 Agios Pharmaceuticals, Inc. Ivosidenib forms and pharmaceutical compositions
US20210299233A1 (en) * 2018-07-12 2021-09-30 The Children's Medical Center Corporation Method for treating cancer
EP3875090A4 (en) * 2018-10-31 2021-12-22 FUJIFILM Corporation PELLET CONTAINING AN ANTITUMOR AGENT
WO2020092906A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
WO2020092915A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
WO2020117867A1 (en) * 2018-12-03 2020-06-11 Beth Israel-Deaconess Medical Center, Inc. Darinaparsin and retinoic acid compounds for treatment of idh-associated disorders
WO2020117868A1 (en) * 2018-12-03 2020-06-11 Beth Israel-Deaconess Medical Center, Inc. Arsenic compounds and retinoic acid compounds for treatment of idh-associated disorders
US12509453B2 (en) 2019-01-29 2025-12-30 Foghorn Therapeutics Inc. BRM/BRG1 inhibitors and uses thereof
IL330104A (en) 2019-03-11 2026-08-01 Deciphera Pharmaceuticals Llc Crystalline forms of rifatinib
KR102035481B1 (ko) 2019-04-12 2019-10-23 한국지질자원연구원 점토광물 복합체를 포함하는 염증성 대장염의 예방, 개선 및 치료용 조성물
US12691108B2 (en) 2019-08-12 2026-07-28 Deciphera Pharmaceuticals, Llc Methods for treating vascular malformations
HRP20260411T1 (hr) 2019-08-12 2026-05-08 Deciphera Pharmaceuticals, Llc Ripretinib za liječenje gastrointestinalnih stromalnih tumora
EP4041922A4 (en) 2019-10-07 2023-11-01 University Hospitals Cleveland Medical Center METHOD FOR TREATING WILD-TYPE ISOCITRATE DEHYDROGENASE-1 CANCER
CN112773797A (zh) * 2019-11-11 2021-05-11 江苏恒瑞医药股份有限公司 一种吡咯并六元杂环化合物在制备治疗flt3突变的肿瘤的药物中的用途
US20220401450A1 (en) * 2019-11-14 2022-12-22 Celgene Corporation Pediatric formulations for treatment of cancer
FI4084779T3 (fi) 2019-12-30 2024-12-16 Deciphera Pharmaceuticals Llc 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
WO2021155264A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155262A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
AU2021242260B2 (en) * 2020-03-23 2023-12-14 Eli Lilly And Company Combination therapy with a mutant IDH inhibitor
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
EP4210766A4 (en) * 2020-09-14 2024-11-06 Totus Medicines Inc. THERAPEUTIC CONJUGATES
CN114681451B (zh) * 2020-11-10 2023-11-03 华熙生物科技股份有限公司 透明质酸或其盐和/或海藻糖的组合物及其在稳定麦角硫因中的用途
US12606553B2 (en) 2021-03-09 2026-04-21 Foghorn Therapeutics Inc. Crystalline forms, compositions containing same, and methods of their use
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
WO2024249769A2 (en) * 2023-06-02 2024-12-05 Foghorn Therapeutics Inc. Combination therapy for treating hematological cancers
CN117838863B (zh) * 2023-12-26 2025-03-11 厦门大学 一种抑制d2hgdh的核酸分子、抑制剂及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
MXPA02007254A (es) 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
CN102985557B (zh) 2009-03-13 2018-06-15 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
CN102438588B (zh) * 2009-03-23 2015-04-01 埃姆比特生物科学公司 使用联合治疗法治疗疾病的方法
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
SMT201800334T1 (it) 2012-01-06 2018-09-13 Agios Pharmaceuticals Inc Composti terapeuticamente attivi e loro metodi di utilizzo
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
BR112015016282A2 (en) * 2013-01-07 2017-07-11 Arog Pharmaceuticals, Inc. crenolanib for treatment of mutated flt3 proliferative disorders
MX375030B (es) 2013-07-11 2025-03-06 Agios Pharmaceuticals Inc Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cancer.
CN105916507A (zh) 2013-08-02 2016-08-31 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
CA2842635A1 (en) 2014-01-20 2015-07-20 University Health Network Pre-cancerous cells and their identification in the prevention and treatment of cancer
WO2015127172A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015127173A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
PH12021551647A1 (en) * 2014-03-14 2022-06-06 Agios Pharmaceuticals Inc Pharmaceutical compositions of therapeutically active compounds
SMT202100444T1 (it) 2014-03-14 2021-09-14 Les Laboratories Servier Sas Composizioni farmaceutiche di composti terapeuticamente attivi
AU2015324158A1 (en) 2014-09-29 2017-04-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3253746A1 (en) 2015-02-04 2017-12-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN108349933A (zh) 2015-08-05 2018-07-31 安吉奥斯医药品有限公司 制备6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二醇和6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二胺的方法

Also Published As

Publication number Publication date
EP3419593B1 (en) 2022-03-23
JP2021102630A (ja) 2021-07-15
US20200261434A1 (en) 2020-08-20
MX2018010252A (es) 2019-01-31
IL261333A (en) 2018-10-31
MX2021007790A (es) 2021-08-11
EP3419593A1 (en) 2019-01-02
CA3015757A1 (en) 2017-08-31
CN109069410A (zh) 2018-12-21
JP2019513694A (ja) 2019-05-30
US10137130B2 (en) 2018-11-27
IL261353A (en) 2018-10-31
AU2016393870A1 (en) 2018-10-18
WO2017146795A1 (en) 2017-08-31
KR20180114202A (ko) 2018-10-17
MX391470B (es) 2025-03-21
MX2018010261A (es) 2019-02-11
JP6930991B2 (ja) 2021-09-01
AU2016393869A1 (en) 2018-09-20
JP2019510746A (ja) 2019-04-18
AU2016393870B2 (en) 2023-01-19
CN109069410B (zh) 2022-05-31
WO2017146794A1 (en) 2017-08-31
EP3419594B1 (en) 2023-07-26
US20190046512A1 (en) 2019-02-14
MX390396B (es) 2025-03-20
CA3015753A1 (en) 2017-08-31
US20170246174A1 (en) 2017-08-31
IL261333B (en) 2022-03-01
JP6856657B2 (ja) 2021-04-07
AU2016393869B2 (en) 2022-10-27
ES2912909T3 (es) 2022-05-30
EP3419594A1 (en) 2019-01-02
MA43640A (fr) 2018-11-28

Similar Documents

Publication Publication Date Title
EP3419593B1 (en) Enasidenib for use in the treatment of relapsed or refractory acute myeloid leukaemia
EP3383400B1 (en) Methods of treatment of malignancies
US10695352B2 (en) Combination therapy for treating malignancies
US20210386749A1 (en) Combination therapy for treating malignancies
EP3493809B1 (en) Enasidenib for treatment of myelodysplastic syndrome
JP7093764B2 (ja) 骨髄異形成症候群の治療方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180823

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211201

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20220927

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240501

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250102

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D